Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure in Heart Failure
45 patients enrolled in study designed to evaluate the ability of cardiopoietic cells to restore cardiac function
17-Dec-2009 -
Cardio3 BioSciences announced that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure. Forty-five patients have now enrolled in the study which is being conducted at centres in ...
Belgium
bone marrow
cell therapies
+4